Promising new cancer therapy appears to be extremely potent against tuberculosis

A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB).

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight

November 13, 2023

Foreign investors fled Chinese biotech after the pandemic. They still haven’t come back

Outside biotech money isn’t pouring into China like it used to. In 2020 and 2021, venture investors put nearly $8 billion into Chinese biopharmas. But

April 6, 2024

How genetic traits contribute to earlier diabetes onset and metabolic challenges in South Asians

The study uncovers genetic factors driving early type 2 diabetes in South Asians, highlighting risks of insulin dependence and medication response challenges.

November 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.